来那度胺对比观察治疗冒烟型多发性骨髓瘤的随机试验
早期干预可显著延迟进展至症状性多发性骨髓瘤及终末器官损害。
要点
- 来那度胺组50%患者出现治疗反应,观察组无反应。
- 3年无进展生存率来那度胺组91%,观察组66%。
核心结论
- 早期用来那度胺干预冒烟型多发性骨髓瘤可显著延迟进展至症状性多发性骨髓瘤及终末器官损害。
研究设计与样本
- 来那度胺口服25 mg,每28天周期第1-21天给药。
- 主要终点为无进展生存期,疾病进展定义为多发性骨髓瘤相关终末器官损害及生化进展。
主要发现
- 中位随访35个月,来那度胺组治疗反应率50%(95%CI 39%-61%),观察组无反应。
- 1年、2年、3年无进展生存率来那度胺组分别为98%、93%、91%,观察组分别为89%、76%、66%。
- 仅报告6例死亡,来那度胺组2例,观察组4例(死亡HR 0.46,95%CI 0.08-2.53)。
- 来那度胺组25例(28%)发生3级或4级非血液学不良事件。
临床怎么用
- 对于中危或高危冒烟型多发性骨髓瘤患者,可考虑早期使用来那度胺干预以延迟疾病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma. METHODS: We conducted a randomized trial that assessed the efficacy of single-agent lenalidomide compared with observation in patients with intermediate- or high-risk smoldering multiple myeloma. Lenalidomide was administered orally at a dose of 25 mg on days 1 to 21 of a 28-day cycle. The primary end point was progression-free survival, with disease progression requiring the development of end-organ damage attributable to multiple myeloma and biochemical progression. RESULTS: One hundred eighty-two patients were randomly assigned-92 patients to the lenalidomide arm and 90 to the observation arm. Median follow-up is 35 months. Response to therapy was observed in 50% (95% CI, 39% to 61%) of patients in the lenalidomide arm, with no responses in the observation arm. Progression-free survival was significantly longer with lenalidomide compared with observation (hazard ratio, 0.28; 95% CI, 0.12 to 0.62; P = .002). One-, 2-, and 3-year progression-free survival was 98%, 93%, and 91% for the lenalidomide arm versus 89%, 76%, and 66% for the observation arm, respectively. Only six deaths have been reported, two in the lenalidomide arm versus four in the observation arm (hazard ratio for death, 0.46; 95% CI, 0.08 to 2.53). Grade 3 or 4 nonhematologic adverse events occurred in 25 patients (28%) on lenalidomide. CONCLUSION: Early intervention with lenalidomide in smoldering multiple myeloma significantly delays progression to symptomatic multiple myeloma and the development of end-organ damage.
引用
- Lonial S, Jacobus S, Fonseca R, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2019. PMID: 31652094. doi:10.1200/JCO.19.01740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。